Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

thehindu.com - N. Ravi Kumar - Economic Survey 2025-26: Pharma industry shifting from volume to value driven approach
Economic Survey 2025-26: Pharma industry shifting from volume to value driven approach
The Hindu

India's pharmaceutical industry is sharpening focus on complex generics, biosimilars and innovation as it moves up the value chain, according to the Economic Survey 2025-26. Third-largest by volume globally and meeting around 20% of global generics…

swissinfo.ch - swissinfo.ch - Swiss pharma firm Roche posts increased 2025 revenue
Swiss pharma firm Roche posts increased 2025 revenue
www.swissinfo.ch

Roche has met its own targets and the outlook for the future also promises further growth, the group announced on Thursday. At constant exchange rates, this represents an increase of 7%, thus achieving its own target of growth in the…

afr.com - Michael Smith - Mayne Pharma to return to court to fight Cosette for failed bid costs
Mayne Pharma to return to court to fight Cosette for failed bid costs
Australian Financial Review

Jilted takeover target Mayne Pharma has pledged to restore shareholder value in the Adelaide-based healthcare group as it returns to court next month to try to recover costs from its long-running legal battle with its former US suitor, Cosette.

newswire.ca - Piramal Pharma Limited Announces Results for Q3 and 9M FY26
Piramal Pharma Limited Announces Results for Q3 and 9M FY26
CNW

MUMBAI, India, Jan. 29, 2026 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine…

thehindubusinessline.com - Broker's call: Piramal Pharma (Reduce)
Broker's call: Piramal Pharma (Reduce)
BusinessLine

Pramal Pharma revenue declined 2.9 per cent y-o-y/grew 4.7 per cent q-o-q to ₹2,139.90 crore (vs Choice International's estimate: ₹2,075.70 crore). EBITDA declined 42 per cent y-o-y/grew 23.3 per cent q-o-q to ₹197.20 crore;…

thehindubusinessline.com - Piramal Pharma posts 'muted' Q3, impacted by 9% dip in CDMO revenues
Piramal Pharma posts 'muted' Q3, impacted by 9% dip in CDMO revenues
BusinessLine

Piramal Pharma's “muted” financial performance for the third quarter (Q3) was due to the destocking of inventory in a large on-patent commercial product by a customer, among other things, the company said. It posted a consolidated…

marketbeat.com - Ruffer LLP Decreases Holdings in Royalty Pharma PLC $RPRX
Ruffer LLP Decreases Holdings in Royalty Pharma PLC $RPRX
MarketBeat

Ruffer LLP lowered its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 26.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 130,184 shares of the biopharmaceutical company's stock…

marketbeat.com - Ascendis Pharma A/S (NASDAQ:ASND) Now Covered by Analysts at Barclays
Ascendis Pharma A/S (NASDAQ:ASND) Now Covered by Analysts at Barclays
MarketBeat

Stock analysts at Barclays assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) in a research note issued on Tuesday, Marketbeat reports. The firm set an 'overweight' rating and a $342.00 price target on the…

globenewswire.com - Alvotech - Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg
GlobeNewswire

REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached a licensing…

globenewswire.com - ALK Abello - ALK receives positive recommendation for EURneffy 1 mg: A needle-free anaphylaxis treatment for children
ALK receives positive recommendation for EURneffy 1 mg: A needle-free anaphylaxis treatment for children
GlobeNewswire

ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP') of the European Medicines Agency has adopted a positive opinion recommending the granting of the marketing authorisation for EURneffy…

cnbc.com - Elsa Ohlen - Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
CNBC

Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a 'patent cliff' where existing drugs lose exclusivity, the companies talked up what they have in the…

wwd.com - James Manso - Why One Beauty Industry Veteran Thinks Allergies Are Wellness's Next Frontier
Why One Beauty Industry Veteran Thinks Allergies Are Wellness's Next Frontier
WWD

One beauty veteran is looking beyond the parameters of the industry's four key categories. Lorne Lucree, consultant and seasoned executive, is bringing beauty's playbook to wellness — more specifically, allergies — which he believes…

telegraph.co.uk - Tom Parry - 'We're gonna need a bigger boat': Shark shortage sparks vaccine supply fears
'We're gonna need a bigger boat': Shark shortage sparks vaccine supply fears
The Telegraph

An international agreement to regulate the overfishing of an endangered species of shark could impact the production of flu and Covid-19 vaccines. Pharma firms including GlaxoSmithKline, Novartis and Sonafi use squalene, commonly derived from the…

scmp.com - Theodora Yu - Hong Kong customs seizes 14,080 smuggled slimming jabs bound for Macau
Hong Kong customs seizes 14,080 smuggled slimming jabs bound for Macau
South China Morning Post

Hong Kong customs have seized more than 14,000 weight-loss injections bound for Macau, days after the South China Morning Post exclusively reported on their suspected illegal sale without prescriptions in the city. The Customs and Excise Department…

seekingalpha.com - Edmund Ingham - Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case (RHHBY)
Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case (RHHBY)
Seeking Alpha

Hoffman-La Roche aka Roche Holding AG delivered robust 2025 results, with core EPS up 11% CER and a resilient pharma division driving growth. RHHBY's pipeline, especially in obesity and cardiovascular, positions it as a potential third major player…

Receive a Daily briefing on Pharma Industry News

Get Started